Stockreport

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update [Yahoo! Finance]

SpyGlass Pharma, Inc.  (SGP) 
PDF Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (I [Read more]